Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Theraclion's annualized positive value of Interest Expense for the quarter that ended in Dec. 2025 was €0.17 Mil. Theraclion's average total debt for the quarter that ended in Dec. 2025 was €4.62 Mil. Therefore, Theraclion's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 was 3.77%.
Theraclion (FRA:941) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Theraclion Effective Interest Rate on Debt % Related Terms
Theraclion Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Theraclion's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theraclion Effective Interest Rate on Debt % Chart
FRA:941 vs ABT, SYK, MDT: Effective Interest Rate on Debt % Comparison
For the Medical Devices subindustry, Theraclion's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theraclion Effective Interest Rate on Debt % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theraclion's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Theraclion's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 3.77% mean?
Theraclion (FRA:941) has a Effective Interest Rate on Debt % of 3.77% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Theraclion and its competitors.
Is Theraclion's Effective Interest Rate on Debt % too high?
Theraclion's current Effective Interest Rate on Debt % is 3.77%. Overall, Theraclion has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theraclion's Effective Interest Rate on Debt % compare to ABT and SYK?
Theraclion's Effective Interest Rate on Debt % of 3.77% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Medical Devices & Instruments company?
A good Effective Interest Rate on Debt % depends on the Medical Devices & Instruments industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Theraclion and its competitors. Theraclion's current Effective Interest Rate on Debt % is 3.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theraclion stock overvalued right now?
Based on GuruFocus' analysis, Theraclion (FRA:941) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €0.54 — trading 125.8% above its estimated fair value. The current Effective Interest Rate on Debt % is 3.77%. Theraclion's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Theraclion (FRA:941), the current Effective Interest Rate on Debt % is 3.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theraclion (FRA:941) Overvalued in 2026?
Based on GuruFocus' analysis, Theraclion stock appears to be overvalued.
The current stock price of €0.54 is trading 125.8% above its estimated GF Value™ of €0.24.
GuruFocus considers Theraclion to be Significantly Overvalued.
Key valuation signals for FRA:941:
Effective Interest Rate on Debt %: 3.77%
GF Value™: €0.24 vs. price of €0.54 (125.8% above fair value)
No single metric tells the full story. See the FRA:941 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theraclion specializes in developing, manufacturing, and marketing echotherapy equipment, associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules. Its products include Sonovein, Echopulse, and Epack.
19GF Score
Get the complete analysis for FRA:941
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:941 has been successfully added to your 
